A 50-year-old woman with a 15-year history of epilepsy was admitted to our hospital due to generalized convulsive status epilepticus. The patient was initially hospitalized in the Intensive Care Unit and then in the Department of Neurology. The repeated magnetic resonance imaging of the head was normal. Extensive diagnostic workup for infectious causes revealed no abnormalities. Cerebrospinal fluid (CSF) examination showed an increased protein level and slightly elevated cytosis with lymphocyte predominance. Antinuclear antibodies (ANA) Hep-2 were detected in serum at a titer of more than 1:2560 (speckled immunofluorescence pattern) without specificity in the immunoblot testing.

Owing to psychotic symptoms, the patient was referred to the Department of Psychiatry for further observation. Confusion, depressed mood, anxiety, as well as visual and auditory hallucinations were reported. Due to persistent epileptiform activity on electroencephalography (Figure 1A), the anti-epileptic treatment was modified: lamotrigine and...
valproic acid were started and carbamazepine was gradually discontinued. As psychotic symptoms persisted, an antipsychotic drug (risperidone) was administered. Laboratory tests revealed reduced levels of hemoglobin (11.1 g/dl), white blood cells (2.52 G/l), neutrophils (0.81 G/l), and platelets (109 G/l). Considering the dynamics of the changes, drug-induced toxicity seemed unlikely.

A consultation with an internist revealed a history of periodic arthralgias and muscle weakness, periodic enlargement and tenderness of the cervical and submandibular lymph nodes (not related to infection), sicca symptoms, as well as flaking skin on the hands and feet. The Schirmer test showed impaired tear secretion (right eye, 8 mm; left eye, 9 mm; reference range, >15 mm), and unstimulated whole saliva flow was significantly reduced (0.1 ml/5 min, reference range, >0.5 ml/5 min).

Based on the medical history and examination, systemic connective tissue disease was suspected. A differential diagnosis included systemic lupus erythematosus (SLE) and primary Sjögren syndrome (pSS). Both are chronic inflammatory autoimmune diseases with possible central nervous system (CNS) involvement. After histopathologic evaluation of the labial salivary glands, which showed typical lymphocytic infiltrates (Figure 1B), the patient was diagnosed with pSS (2016 American College of Rheumatology/European League Against Rheumatism criteria were fulfilled). Lumbar puncture was performed to assess whether neuropsychiatric symptoms might result from CNS involvement in the course of pSS. Improvement of the general condition and complete resolution of neuropsychiatric symptoms were observed after immunosuppressive treatment with intravenous methylprednisolone pulses (5 × 500 mg), followed by oral prednisone (1 mg/kg) and intravenous cyclophosphamide infusions (15 mg/kg once a month for 6 months). This case, along with other reports, emphasizes the need for an interdisciplinary approach to the management of rheumatic diseases.

ARTICLE INFORMATION

CONFLICT OF INTEREST MSW has received research support from Acadia, Actavis, Alkermes, Allergan, Apoepemus, Auspex, Biogen, Bristol-Myers Squibb, Cephalon, Celon, Eli Lilly, Ferrer, Forest Laboratories, Gedeon Richter, GW Pharmaceuticals, Janssen, KCR, Lundbeck, NIH, NeuroCog, Orion, Otsuka, Sanofi, and Servier; he has served on speakers bureaus for Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Kira, Lekam, Lundbeck, Novartis, Orion, Pfizer, Poffa Tarchonins, Sanofi, Servier, and Zenotva; he has served as a consultant for GW Pharmaceuticals, Janssen, KCR, Quintiles, and Roche. Other authors declare no conflict of interest.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Sharable license 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.


REFERENCES


CLINICAL IMAGE Neuropsychiatric presentation of Sjögren syndrome 69